Novakid Maintains Growth in 2022, Launches 40-Minute Learning Sessions
22.2.2023 18:00:00 EET | Business Wire | Press release
Novakid, a leading online English as a Second Language (ESL) platform and evolving EdTech company that is reinventing learning for children, maintained customer growth with approximately 70,000 new students across 50+ countries subscribing during 2022.
Importantly, Novakid achieved double-digit YoY revenue growth, with the share of long-term subscriptions (6 and 12 months) steadily increasing. Globally, over 20% of new subscription sales are attributed to referrals from current customers and NPS is trending at above 60% (best in class), evident in the improved customer retention figures. Novakid maintained high scores for customer satisfaction - an average of 96%, depending on the region - based on internal measurement methods conducted on a regular basis.
Over 10 million lessons have been delivered since 2017, of which nearly 4.5 million lessons (4,453,732) were completed in 2022.
Novakid continued to strengthen its positions in global markets. Europe still accounts for the majority of the company’s client portfolio (55%) with the MENA region accounting for 25% of the client base and the Asia-Pacific region increasing to 20% of the total number of customers.
2023 plans
The 25-minute one-on-one English lesson format will be upgraded to a 40-minute educational journey for young students. These extended sessions are at no additional cost to clients and include three elements: a fun, context-setting pre-lesson activity, the one-on-one lesson with a teacher and gamified self-practice ‘homework’ after the lesson. Since August 2022, Novakid has noted that the average time students spend on self-practice activities beyond structured, one-to-one lessons has tripled.
New product developments that are being considered for the platform are aimed at increasing the engagement with educational content to increase motivation to learn and support learning outcomes. The team is constantly researching and testing various options, including experiments with other subjects that could be added to the product line.
Recent research has indicated that increased time spent on homework and mini games has a positive impact on the retention rate. Additionally, the monthly retention rate of users who have watched comic-based videos is 149% higher than those who have not. Ultimately, more interaction with games, videos and additional content results in higher retention rates. This insight will drive curriculum and product development going forward.
“Our focus in the upcoming year will lie on further improving the value of our product for our customers. We will do this by continuing to invest in better UX for customers, and in high-quality content for our teachers helping them to be even better at teaching. We will continue expanding our offering beyond the one-to-one tutoring format. Specifically, we are planning to add self-learning activities and start introducing 1-many learning & practice products. We are grateful for the trust that our families put in us to teach their children. The results of our young English learners remain the biggest achievement for Novakid,” said Max Azarov, CEO of Novakid.
For more information about Novakid, please visit https://www.novakidschool.com/corp/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005563/en/
Contact information
Dominique Harmse, +447932928310
dominique.harmse@novakidschool.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
